RTIX - RTI Surgical Holdings Inc.® Provides Business Updates
DEERFIELD, Ill., June 30, 2020 (GLOBE NEWSWIRE) -- RTI Surgical Holdings, Inc. (Nasdaq: RTIX), a global surgical implant company, today provided a business update in conjunction with releasing financial and operating results for the quarter ended March 31, 2020.
Business Update Highlights:
- Scheduled special meeting of stockholders for July 15, 2020 to vote on sale of OEM business
- Announced two senior leadership appointments and a new director to support transition to a pure-play global spine company
- First quarter 2020:
-
- Revenue of $73.7 million, up 5% compared to the first quarter of 2019
- Net loss of $17.9 million, or $0.24 per common share
- Adjusted EBITDA of $1.4 million, or 2% of revenue
“I am very proud of the actions taken by our entire organization over the last several months as we have navigated the COVID-19 pandemic while at the same time managing through the pending sale of the OEM business and a number of other headwinds,” said Camille Farhat, President and CEO, RTI Surgical. “The integrity, dedication, and talent of our people have enabled us to come out on the other side of this unique period in time ready to take advantage of the opportunities that exist in the Spine market for high-value surgical solutions.”
Farhat continued, “We view the recent disruption as transitory, and despite the uncertainty associated with COVID-19, we remain very confident in the long-term prospects of the Spine business. We are targeting double-digit long-term revenue growth with gross margins of 75% by executing on our strategy of build, innovate, and acquire. We are very excited about this next phase of RTI’s transformation.”
Annual Meeting and Special Meeting of Stockholders
The company will hold its annual meeting of stockholders on July 15, 2020. Among the matters to be considered and voted on at the Annual Meeting, which, as previously disclosed, will be combined with a special meeting of the stockholders, are the various proposals necessary to approve the transactions contemplated by the previously announced Equity Purchase Agreement, dated January 13, 2020, as amended, with Ardi Bidco Ltd., a Delaware corporation and an entity affiliated with Montagu Private Equity, LLP (the “Buyer”), pursuant to which the Buyer will acquire the OEM business of the Company by means of a sale of certain affiliates of the Company.
Spine Business Update
On June 10, 2020 The Company announced two senior leadership appointments to support its transition to a pure-play global spine company. Scott Durall joined RTI as Chief Commercial Officer, and Bryan Cornwall joined RTI as Executive Vice President, Research and Clinical Affairs, both effective June 15, 2020. Durall and Cornwall bring to RTI decades of commercial, operational and scientific expertise, and will support the Company’s ongoing focus on becoming a leader in the global spine market following the close of the pending sale of the OEM business. Please see our related press release for more detail on their backgrounds.
In addition, on June 1, Stuart F. Simpson joined the Board of Directors and was recently named Vice Chairman of the Board. Mr. Simpson brings decades of industry experience which will be valuable in supporting RTI’s strategy as a pure-play global spine company.
First Quarter 2020 Financial Results
RTI’s worldwide revenues for the first quarter of 2020 were $73.7 million, an increase of $3.7 million, or 5% compared with $70.0 million during the same period in the prior year. Gross profit for the first quarter of 2020 was $40.5 million, or 55% of revenues, a 7.0% increase compared to $37.9 million, or 54% of revenues, in the first quarter of 2019.
Net loss applicable to common shares was $17.9 million, or $0.24 per fully diluted common share in the first quarter of 2020, compared to net loss applicable to common shares of $9.4 million, or $0.14 per fully diluted common share in the first quarter of 2019.
Adjusted earnings before interest, taxes, depreciation and amortization (Adjusted EBITDA), for the first quarter of 2020 was $1.4 million, or 2% of revenues, compared with $7.0 million, or 10% of revenues for the first quarter of 2019. The decrease in Adjusted EBITDA was primarily driven by annualization of costs related to the Paradigm acquisition and incremental investment for the separation of the business to support the sale of the OEM business.
2020 Outlook
Due to the inability to estimate the size and impact of the COVID-19 pandemic on the Company’s operations and financial results, RTI Surgical Holdings, Inc. will not provide guidance for fiscal year 2020. We will continue to evaluate the COVID-19 pandemic on our operations and financial results and will provide additional information when we are more certain.
Conference Call
RTI will host a conference call and audio webcast at 9:00 a.m. ET today. The conference call can be accessed by dialing (877) 383-7419 (U.S.) or (760) 666-3754 (International), using conference ID 6346397. The webcast can be accessed through the investor section of RTI’s website at www.rtix.com/investors. A replay of the conference call will be available on RTI’s website for one month following the call.
About RTI Surgical Holdings, Inc.
RTI Surgical Holdings is a leading global surgical implant company providing surgeons with safe biologic, metal and synthetic implants. Committed to delivering a higher standard, RTI’s implants are used in sports medicine, plastic surgery, spine, orthopedic and trauma procedures and are distributed in over 50 countries. RTI has four manufacturing facilities throughout the U.S. and Europe. RTI is accredited in the U.S. by the American Association of Tissue Banks and is a member of AdvaMed. For more information, please visit www.rtix.com. Connect with us on LinkedIn and Twitter.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based on management’s current expectations, estimates and projections about our industry, our management’s beliefs and certain assumptions made by our management. Words such as “anticipates,” “expects,” “intends,” “plans,” “believes,” “seeks,” “estimates,” variations of such words and similar expressions are intended to identify such forward-looking statements. The forward-looking statements are not guarantees of future performance and are based on certain assumptions including general economic conditions, as well as those within the Company’s industry, and numerous other factors and risks identified in the Company’s Form 10-K for the fiscal year ended December 31, 2019 and other filings with the SEC. Our actual results may differ materially from the anticipated results reflected in these forward-looking statements. Important factors that could cause actual results to differ materially from the anticipated results reflected in these forward-looking statements include risks and uncertainties relating to the following: (i) the risk of existing or potential litigation or regulatory action arising from the previously announced internal investigation and its findings or from the failure to timely file the Form 10-K; (ii) the identification of control deficiencies, including material weaknesses in internal control over financial reporting and the impact of the same; (iii) potential reputational damage that the Company has or may suffer as a result of the ultimate findings of the investigation; (iv) general worldwide economic conditions and related uncertainties; (v) the anticipated impact of the COVID-19 novel coronavirus pandemic and the Company’s attempts at mitigation; (vi) the failure by the Company to identify, develop and successfully implement immediate action plans and longer-term strategic initiatives; (vii) our ability to continue production; (viii) the reliability of our supply chain; (ix) our ability to meet obligations under our debt or material agreements; (x) the duration of decreased demand for our products; (xi) our ability to continue to recall furloughed employees; (xii) whether or when the demand for procedures will increase; (xiii) the Company’s access to adequate operating cash flow, trade credit, borrowed funds and capital to fund its operations and pay its obligations as they become due, including the impact of adverse trends or disruption in the global credit and equity markets; (xiv) our financial position and results, total revenue, product revenue, gross margin, and operations; (xv) the risk that the Company may be unable to obtain shareholder approval for the proposed transaction; (xvi) the risk that a condition to the closing of the proposed transaction may not be satisfied; (xvii) the risk that the occurrence of an event that could give rise to termination of the definitive agreement; (xviii) the risk that shareholder litigation in connection with the proposed transaction may affect the timing or occurrence of the proposed transaction or result in significant costs of defense, indemnification and liability; (xix) the timing to consummate the proposed transaction; (xx) the effect of the announcement or disruption from the proposed transaction making it more difficult to retain and hire key personnel and maintain relationships with customers, suppliers and other third parties; (xxi) the diversion of management time and attention on the proposed transaction; (xxii) the effect and timing of changes in laws or in governmental regulations; and (xxiii) other risks described in our public filings with the SEC. These factors should be considered carefully and undue reliance should not be placed on the forward-looking statements. Each forward-looking statement in this communication speaks only as of the date of the particular statement. Copies of the Company’s SEC filings may be obtained by contacting the Company or the SEC or by visiting RTI’s website at www.rtix.com or the SEC’s website at www.sec.gov. We undertake no obligation to update these forward-looking statements except as may be required by law.
| RTI SURGICAL HOLDINGS, INC. AND SUBSIDIARIES |
| Condensed Consolidated Statements of Operations |
| (Unaudited, in thousands, except share and per share data) |
| For the Three Months Ended |
| March 31, |
| 2020 |
| 2019 |
| Revenues |
| $ |
| 73,726 |
| $ |
| 70,021 |
| Costs of processing and distribution |
| 33,273 |
| 32,134 |
| Gross profit |
| 40,453 |
| 37,887 |
| Expenses: |
| Marketing, general and administrative |
| 39,217 |
| 32,116 |
| Research and development |
| 4,282 |
| 4,336 |
| Asset impairment and abandonments |
| 1,879 |
| 15 |
| Other general expenses |
| 3,436 |
| - |
| Transaction and integration expenses |
| 9,280 |
| 8,957 |
| Total operating expenses |
| 58,094 |
| 45,424 |
| Operating loss |
| (17,641 |
| ) |
| (7,537 |
| ) |
| Total other expense - net |
| (3,761 |
| ) |
| (1,504 |
| ) |
| Loss before income tax benefit (expense) |
| (21,402 |
| ) |
| (9,041 |
| ) |
| Income tax benefit (expense) |
| 3,539 |
| (310 |
| ) |
| Net loss |
| (17,863 |
| ) |
| (9,351 |
| ) |
| Convertible preferred dividend |
| - |
| - |
| Net loss applicable to common shares |
| $ |
| (17,863 |
| ) |
| $ |
| (9,351 |
| ) |
| Net loss per common share - basic |
| $ |
| (0.24 |
| ) |
| $ |
| (0.14 |
| ) |
| Net loss per common share - diluted |
| $ |
| (0.24 |
| ) |
| $ |
| (0.14 |
| ) |
| Weighted average shares outstanding - basic |
| 75,847,046 |
| 65,675,203 |
| Weighted average shares outstanding - diluted |
| 75,847,046 |
| 65,675,203 |
| RTI SURGICAL HOLDINGS, INC. AND SUBSIDIARIES |
| Reconciliation of Revenues to Adjusted Gross Profit |
| (Unaudited, in thousands) |
| For the Three Months Ended |
| March 31, |
| 2020 |
| 2019 |
| Revenues |
| $ |
| 73,726 |
| $ |
| 70,021 |
| Costs of processing and distribution |
| 33,273 |
| 32,134 |
| Gross profit, as reported |
| 40,453 |
| 37,887 |
| Inventory write-off |
| 48 |
| - |
| Inventory purchase price adjustment |
| 878 |
| - |
| Non-GAAP gross profit, adjusted |
| $ |
| 41,379 |
| $ |
| 37,887 |
| Non-GAAP gross profit percentage, adjusted |
| 56.1 |
| % |
| 54.1 |
| % |
| RTI SURGICAL HOLDINGS, INC. AND SUBSIDIARIES |
| Reconciliation of Net Loss Applicable to Commons Shares to Adjusted EBITDA |
| (Unaudited, in thousands) |
| For the Three Months Ended |
| March 31, |
| 2020 |
| 2019 |
| Net loss applicable to common shares |
| $ |
| (17,863 |
| ) |
| $ |
| (9,351 |
| ) |
| Interest expense, net |
| 3,515 |
| 1,473 |
| Provision for income taxes |
| (3,539 |
| ) |
| 310 |
| Depreciation |
| 1,766 |
| 3,443 |
| Amortization of intangible assets |
| 473 |
| 957 |
| EBITDA |
| (15,648 |
| ) |
| (3,168 |
| ) |
| Reconciling items impacting EBITDA |
| Preferred dividend |
| - |
| - |
| Non-cash stock based compensation |
| 1,310 |
| 1,163 |
| Foreign exchange gain (loss) |
| 246 |
| 31 |
| Other reconciling items * |
| Inventory write-off |
| 48 |
| - |
| Inventory purchase price adjustment |
| 878 |
| - |
| Other general expenses |
| 3,436 |
| - |
| Asset impairment and abandonments |
| 1,879 |
| - |
| Transaction and integration expenses |
| 9,280 |
| 8,957 |
| Adjusted EBITDA |
| $ |
| 1,429 |
| $ |
| 6,983 |
| Adjusted EBITDA as a percent of revenues |
| 1.9 |
| % |
| 10.0 |
| % |
| *See explanations in Use of Non-GAAP Financial Measures section later in this release. |
| RTI SURGICAL HOLDINGS, INC. AND SUBSIDIARIES |
| Reconciliation of Net Income (Loss) Applicable to Common Shares and Net Income (Loss) Per Diluted Share to |
| Adjusted Net Income Applicable to Common Shares and Adjusted Net Income Per Diluted Share |
| (Unaudited, in thousands except per share data) |
| For the Three Months Ended |
| March 31, 2020 |
| March 31, 2019 |
| Net |
| Net |
| Income (Loss) |
| Amount |
| Income (Loss) |
| Amount |
| Applicable to |
| Per Diluted |
| Applicable to |
| Per Diluted |
| Common Shares |
| Share |
| Common Shares |
| Share |
| As reported |
| $ |
| (17,863 |
| ) |
| $ |
| (0.24 |
| ) |
| $ |
| (9,351 |
| ) |
| $ |
| (0.14 |
| ) |
| Asset impairment and abandonments |
| 1,879 |
| 0.02 |
| - |
| - |
| Inventory purchase price adjustment |
| 878 |
| 0.01 |
| - |
| - |
| Other general expenses |
| 3,436 |
| 0.05 |
| - |
| - |
| Inventory write-off |
| 48 |
| 0.00 |
| - |
| - |
| Transaction and integration expenses |
| 9,280 |
| 0.12 |
| 8,957 |
| 0.14 |
| Tax effect on adjustments |
| - |
| - |
| 617 |
| 0.01 |
| Adjusted * |
| $ |
| (2,342 |
| ) |
| $ |
| (0.03 |
| ) |
| $ |
| 223 |
| $ |
| 0.00 |
| * See explanations in Use of Non-GAAP Financial Measures section later in this release. |
| Amount Per Diluted Share may not foot due to rounding. |
Use of Non-GAAP Financial Measures
To supplement the Company’s unaudited condensed consolidated financial statements presented on a GAAP basis, the Company discloses certain non-GAAP financial measures that exclude certain amounts, including EBITDA, Adjusted EBITDA and Adjusted Net Income Applicable to Common Shares. The calculation of the tax effect on the adjustments between GAAP net loss applicable to common shares and non-GAAP net income applicable to common shares is based upon our estimated annual GAAP tax rate, adjusted to account for items excluded from GAAP net loss applicable to common shares in calculating Adjusted Net Income Applicable to Common Shares-Diluted. A reconciliation of the non-GAAP financial measures to the corresponding GAAP measures is included in the tables listed above.
The following are explanations of the adjustments that management excluded as part of the non-GAAP measures for the three months ended March 31, 2020 and 2019. Management removes the amount of these costs including the tax effect on the adjustments from our operating results to supplement a comparison to our past operating performance.
2020 Asset impairment and abandonments – These costs relate to asset impairment and abandonments of certain long-term assets within the Spine asset group.
2020 Other general expenses – These costs relate to consulting and legal fees and settlement expenses incurred as a result of the restatement, regulatory and related activities in 2020.
2020 Transaction and integration expenses – These costs relate to transaction and separation expenses due the Sale of OEM in 2020.
2020 Inventory purchase price adjustment – These costs relate to the purchase price effects of acquired Paradigm inventory that was sold during the three months ended March 31, 2020.
2019 Transaction and integration expenses – These costs relate to acquisition and integration expenses due to the purchase of Paradigm in 2019.
Material Limitations Associated with the Use of Non-GAAP Financial Measures
EBITDA, Adjusted EBITDA and Adjusted Net Income Applicable to Common Shares should not be considered in isolation, or as a replacement for GAAP measures.
Usefulness of Non-GAAP Financial Measures to Investors
The Company believes that presenting EBITDA, Adjusted EBITDA and Adjusted Net Income Applicable to Common Shares in addition to the related GAAP measures provide investors greater transparency to the information used by management in its financial decision-making. The Company further believes that providing this information better enables the Company’s investors to understand the Company’s overall core performance and to evaluate the methodology used by management to assess and measure such performance.
| RTI SURGICAL HOLDINGS, INC. AND SUBSIDIARIES |
| Condensed Consolidated Revenues |
| (Unaudited, in thousands) |
| For the Three Months Ended |
| March 31, |
| 2020 |
| 2019 |
| Revenues: |
| Spine |
| $ |
| 27,109 |
| $ |
| 24,377 |
| OEM |
| 46,617 |
| 45,644 |
| Total revenues |
| $ |
| 73,726 |
| $ |
| 70,021 |
| RTI SURGICAL HOLDINGS, INC. AND SUBSIDIARIES |
| Condensed Consolidated Balance Sheets |
| (Unaudited, in thousands) |
| March 31, |
| December 31, |
| 2020 |
| 2019 |
| Assets |
| Cash |
| $ |
| 6,557 |
| $ |
| 5,608 |
| Accounts receivable - net |
| 54,921 |
| 59,288 |
| Inventories - net |
| 126,760 |
| 124,149 |
| Prepaid and other assets |
| 8,422 |
| 6,769 |
| Total current assets |
| 196,660 |
| 195,814 |
| Non-current inventories - net |
| 5,891 |
| 6,637 |
| Property, plant and equipment - net |
| 70,716 |
| 69,890 |
| Goodwill |
| 55,384 |
| 55,384 |
| Other assets - net |
| 16,419 |
| 16,784 |
| Total assets |
| $ |
| 345,070 |
| $ |
| 344,509 |
| Liabilities and Stockholders' Equity |
| Accounts payable |
| $ |
| 38,520 |
| $ |
| 30,126 |
| Accrued expenses and other current liabilities |
| 43,364 |
| 36,085 |
| Current portion of long-term obligations |
| 175,673 |
| 174,177 |
| Total current liabilities |
| 257,557 |
| 240,388 |
| Long-term liabilities |
| 3,633 |
| 3,147 |
| Total liabilities |
| 261,190 |
| 243,535 |
| Preferred stock |
| 66,456 |
| 66,410 |
| Stockholders' equity: |
| Common stock and additional paid-in capital |
| 494,465 |
| 493,372 |
| Accumulated other comprehensive loss |
| (7,999 |
| ) |
| (7,629 |
| ) |
| Accumulated deficit |
| (469,042 |
| ) |
| (451,179 |
| ) |
| Total stockholders' equity |
| 17,424 |
| 34,564 |
| Total liabilities and stockholders' equity |
| $ |
| 345,070 |
| $ |
| 344,509 |
| RTI SURGICAL HOLDINGS, INC. AND SUBSIDIARIES |
| Condensed Consolidated Statements of Cash Flows |
| (Unaudited, in thousands) |
| For the Three Months Ended |
| March 31, |
| 2020 |
| 2019 |
| Cash flows from operating activities: |
| Net loss |
| $ |
| (17,863 |
| ) |
| $ |
| (9,351 |
| ) |
| Adjustments to reconcile net loss to net cash provided by (used in) operating activities: |
| Depreciation and amortization expense |
| 2,239 |
| 4,400 |
| Stock-based compensation |
| 1,310 |
| 1,163 |
| Amortization of deferred revenue |
| (1,188 |
| ) |
| (1,292 |
| ) |
| Other items to reconcile to net cash |
| used in operating activities |
| 22,018 |
| (10,477 |
| ) |
| Net cash provided by (used in) operating activities |
| 6,516 |
| (15,557 |
| ) |
| Cash flows from investing activities: |
| Purchases of property, plant and equipment |
| (5,084 |
| ) |
| (3,477 |
| ) |
| Patent and acquired intangible asset costs |
| (286 |
| ) |
| (328 |
| ) |
| Acquisition of Paradigm Spine |
| - |
| (99,921 |
| ) |
| Net cash used in investing activities |
| (5,370 |
| ) |
| (103,726 |
| ) |
| Cash flows from financing activities: |
| Proceeds from long-term obligations |
| - |
| 115,000 |
| Payments of debt issuance costs |
| - |
| (729 |
| ) |
| Payments for treasury stock |
| (193 |
| ) |
| - |
| Other financing activities |
| 20 |
| 156 |
| Net cash (used in) provided by financing activities |
| (173 |
| ) |
| 114,427 |
| Effect of exchange rate changes on cash and cash equivalents |
| (24 |
| ) |
| (50 |
| ) |
| Net increase (decrease) in cash and cash equivalents |
| 949 |
| (4,906 |
| ) |
| Cash and cash equivalents, beginning of period |
| 5,608 |
| 10,949 |
| Cash and cash equivalents, end of period |
| $ |
| 6,557 |
| $ |
| 6,043 |
Jonathon Singer
Investor and Media Contact
jsinger@rtix.com
+1 877-343-6832